natgillin/translations-raw huggingface dataset:
alkyl optionally substituted with one to three groups selected from the group consisting of alkoxy, alkoxyalkoxy, cycloalkyl, phenyl and halogen. 
alkil, izborno supstituiran s jednom do tri skupine, koje se bira iz skupine koju čine alkoksi, alkoksialkoksi, cikloalkil, fenil i halogen.
The thermoplastic film according to any preceding claim, wherein the base film and the fibre element are prestretched by at least 10%, preferably by at least 50%, preferably by at least 100%, more preferably by at least 200%. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu su osnovna folija 1 element vlakana prethodno rastegnuti za barem 10%, poželjno za barem 50%, poželjno za barem 100%, poželjnije za barem 200%.
reacting said purified Compound 8 with a secondary amine and a carboxylic acid in a first solvent to produce Compound 10: and, 
(d) reakciji navedenog pročišćenog Spoja 8 sekundarnim aminom i karboksilnom kiselinom u prvom otapalu kako bi se dobilo Spoj 10: i
A substance delivery system comprising at least one polymeric material forming a matrix and an anabolic drug, wherein the at least one polymeric material comprises collagen and wherein said anabolic drug is included in the at least one polymeric material forming the matrix, wherein the matrix is a biphasic scaffold or a biphasic membrane, and wherein the anabolic drug is an FGF-18 polypeptide comprising SEQ ID NO: 1 or a fragment thereof having chondrocyte or osteoblast proliferation activity or cartilage formation activity, and wherein the anabolic drug is present at a dose from 20 to 100 mcg/system. 
Sustav za primjenu tvari koji sadrži najmanje jedan polimerni materijal koji tvori matricu i anabolički lijek, naznačen time što barem jedan polimerni materijal je kolagen i pri čemu je navedeni anabolički lijek uključen u barem jedan polimerni materijal koji tvori matricu, pri čemu je matrica dvofazni skelet ili dvofazna membrana, i pri čemu anabolički lijek je spoj FGF-18 u dozi od 5 do 100 mikrograma/sustavu.
CDRH2 comprises a sequence selected from the group consisting of SEQ ID NOs: 24-26 or a variant thereof; and CDRH3 comprises the sequence of SEQ ID NO: 31 or a variant thereof; wherein each variant comprises up to five conservatively modified amino acid substitutions. 
CDRH2 sadrži sekvencu SEQ ID NO: 25; 1 CDRH3 sadrži sekvencu prema SEQ ID NO: 31 ili njenu varijantu; gdje svaka varijanta sadrži do jednu konzervativno modificiranu aminokiselinsku supstituciju.
The compound or salt or pharmaceutical composition for the use of Claim 23, wherein the lymphoid malignancy is non-Hodgkin's lymphoma, chronic lymphoid leukemia, or acute lymphocytic leukemia. 
Spoj ili sol ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 23, naznačen time, da je limfoidni maligni tumor (maligni tumor) ne-Hodgkinov limfom, kronična limfoidna leukemija ili akutna limfocitna leukemija.
Step a) Conversion of carboxy group of a compound of formula (III) to carbamate to form a compound of formula (IV) wherein R is C1-6alkyl, C1-6alkoxyphenyl-CxH2x- or phenyl-CxH2x-; 
Korak a) Pretvorba karboksi skupine spoja formule (III) [image] u karbamat, kako bi se tvorio spoj formule (IV) [image] u kojoj R je kao što je gore definirano;
A compound for use according to claim 5, wherein the disease state is selected from a group consisting of: atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and vasoconstriction. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: ateroskleroza, hipertrofija srca, disfunkcija kardiomiocita, povišeni krvni tlak i vazokonstrikcija.
The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-l-naphthalenamine and its pharmaceutically acceptable acid addition salts. 
Poželjna realizacija je enantiomer cis-(15)-N-metil-4-(3,4-diklorofenil)-1,2,3,4-tetrahidro-1-naftalinamina i njegove aditivne farmaceutski prihvatljive soli s kiselinama.
In another embodiment of the disclosure, the process further comprises exposing the neutralized and cooled gaseous mixture to conditions effective to reduce residual organic compounds. In another embodiment, the conditions to reduce residual organic compounds in the neutralized and cooled gaseous mixture comprise UV light at a wavelength of about 200 nm to about 300 nm in the presence of an excess amount of hydrogen gas. 
Postupak prema zahtjevu 7, naznačen time da nadalje sadrži izlaganje neutralizirane i ohlađene plinske smjese u prisutnosti suvišne količine plinovitog vodika uvjetima koji su učinkoviti za smanjivanje zaostalih organskih spojeva, pri čemu uvjeti sadrže UV svijetlo kod valne duljine od 200 nm do 300 nm, poželjnije UV svijetlo kod valne duljine od 220 nm do 254 nm.
Either such reside has to be removed, washed out, or the bottle has to be discarded permanently. 
Takav ostatak se mora odstraniti i isprati, ili se bocu mora trajno odbaciti.
The compound or composition for use according to claim 21, wherein the immunological or inflammatory disease is organ transplant. 
Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 14, gdje su imunološko ili inflamatorno oboljenje presađeni organ.
The term “stringent conditions” refers to hybridisation and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as “stringent”. 
Pojam "strogi uvjeti" odnosi se na hibridizaciju i naknade korake ispiranja, koje bi stručnjaci konvencionalno nazvali "strogim".
The solution was then diluted with dichloromethane (200mL) and washed with water (2 x 200mL). 
Otopinu se zatim razrijedi diklormetanom (200 ml), te ispere s vodom (2 x 200 ml).
The thickness s of the corrugated side wall 2 of the core is fairly small. 
Debljina s valovite bočne stijenke 2 na jezgri, je prilično mala.
The apparatus of claim 1, further comprising an additional inlet for receiving an additional fluid from an additional source, wherein the gas chromatograph is coupled to the additional inlet and receives a sample of the additional fluid. 
Uređaj prema bilo kojem od gornjih zahtjeva, naznačen time da nadalje sadrži dodatni dovod (108) za primanje dodatnog fluida iz dodatnog izvora (110), pri čemu je plinski kromatograf (114) spojen na dodatni dovod (108) za primanje uzorka dodatnog fluida.
Cortexolone-17a-propionate in crystalline form III according to anyone of claims 15 to 18 for use in the treatment pathologies affecting the urogenital system, the endocrine system, the skin, and/or the cutaneous appendages. 
Korteksolon-17a-propionat u hidratnom kristalnom obliku IV u skladu s bilo kojim od patentnih zahtjeva 21 do 22, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožnih adneksa.
"heteroaryl" refers to a 5-14 membered aromatic ring system having 1-3 ring heteroatoms if monocyclic, 1-6 ring heteroatoms if bicyclic, or 1-9 ring heteroatoms if tricyclic, said ring heteroatoms being independently selected from O, N, and S; 
"heteroaril" označava 5-14 -člani aromatični sistem prstena koji ima 1-3 heteroatoma u prstenu ako je monocikličan, 1-6 heteroatoma u prstenu ako je bicikličan ili 1 -9 heteroatoma u prstenu ako je tricikličan, pri čemu su navedeni heteroatomi prstena nezavisno izabrani od O, N 1 S;
A compound which is 2-(3,5-Dichloro-1-oxido-pyridine-4-yl)-1-(7-difluoromethoxy-2',3',5',6'-tetrahydro-spiro[1,3-benzodioxole-2,4'-(4H)-thiopyran-1',1'-dioxide]-4-yl)ethanone, or a pharmaceutically acceptable hydrate or solvate thereof, for use in the treatment of proliferative and inflammatory skin disorders such as psoriasis, epidermal inflammation, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis and eczema. 
Spoj koji je 2-(3,5-Dikloro-1-oksido-piridin-4-il)-1-(7-difluorometoksi-2*,3',5',6'-tetrahidro-spiro[1,3benzodioksol-2,4'-(4H)-tiopiran-1',1*-dioksid]|-4-iljetanon, ili parmaceutski prihvatljiv hidrat ili solvat istih, za uporabu u liječenju proliferativnih i upalnih kožnih poremećaja poput psorijaze, epidermalne upale, akni, dermatitisa, atopijskog dermatitisa, seboreičnog dermatitisa, kontaktnog dermatitisa, urtikarije, pruritisa i ekcema.
A cloning or expression vector comprising the nucleic acid according to claim 1 . 
Vektor kloniranja ili ekspresije, naznačen time, da obuhvaća jednu ili više nukleinskih kiselina prema zahtjevu 11.
For treatment of incontinence, the diameter of the part, which is to be introduced through the urethra, is preferably 7-8 mm. 
Za liječenje inkontinencije poželjno je da promjer dijela koji se treba uvesti kroz mokraćovod iznosi 7 - 8 mm.
The heating system according to claim 1, wherein said heat exchanger is configured to provide a galvanic separation of said primary heating liquid from said secondary heating liquid. 
Sustav grijanja (100) u skladu s patentnim zahtjevom 1, naznačen time što je navedeni izmjenjivač topline (130) konfiguriran da osigura galvansko odvajanje (134) navedene primarne tekućine grijanja od sekundarne tekućine grijanja.
the organoid comprises a single layered epithelial domain where polarized cells are detected and keratin markers are expressed and a second domain, constituting the main body of the organoid, formed by a multilayered epithelia with non-polarized cells, optionally expressing albumin, and/or the organoid originates from a cell expressing Lgr5, and which comprises a population of between at least 1x103 cells and 5x104, for example between at least 1x103 cells and 5x103 cells. 
(a) organoid obuhvaća jednoslojno epitelno područje gdje se detektiraju polarizirane stanice 1 markeri keratina su izraženi i drugo područje, koje čini glavno tijelo organoida, obrazovano višeslojnim epitelijem sa ne-polariziranim stanicama, koje opcionalno eksprimiraju albumin, i/ili (b) organoid je dobiven 1z epitelijalne matične stanice iz odrasle jetre koja eksprimira Lgr5, i koja sadrži populaciju između najmanje 1x10* stanica i 5x10".
Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs, and pressurized compositions. 
Tekući nosači koriste se u pripremi otopina, suspenzija, emulzija, sirupa, eliksira i pripravaka pod tlakom.
The method of claim 19, wherein the medicament is for topical administration and is selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 
Uporaba patentnih zahtjeva 1-8, naznačena time, da je lijek u obliku odabranom iz skupine koja se sastoji od zrnaca, praška, granula, raspršivača, transdermalnih naljepaka, krema, losiona i otopina za grgljanje (kolirij).
The method of claim 1, wherein the pharmaceutical composition is administered in a solid dosage form. 
Farmaceutska dozna formulacija iz patentnog zahtjeva 1, naznačena time što je formulacija čvrsti dozni oblik.
The compound according to claim 1 for use as in claim 1, wherein R3 and R'3 together with the carbon atom to which they are attached form a C3-7 cycloaliphatic, in particular a cyclopropyl ring. 
N o] HI Spoj prema zahtjevu 1, naznačen time da R; i R's zajedno s atomom ugljika na koji su vezani tvore C3; cikloalifatski, naročito ciklopropilni prsten.
in which means an aryl which may optionally be substituted with 1-3 alkyl, hydroxy, halogen, cyano or C1-C5-alkoxygroups or a heteroarylgroup in which the heteroarylgroup may contain 1-3 heteroatoms which may optionally be substituted with 1-3 alkyl, hydroxy, halogen, cyano or C1-C5-alkoxygroups, 
predstavlja aril koji može biti proizvoljno supstituiran sa 1-3 alkil, hidroksi, halogen, cijano ili C1-C5-alkoksi skupine ili heteroaril skupinom gdje heteroarilna skupina može sadržavati 1-3 heteroatoma koji mogu biti proizvoljno supstituirani sa 1-3 alkil, hidroksi, halogen, cijano ili C1-C5-alkoksi skupine, n predstavlja cijeli broj koji je odabran od 1, 2, 3, 4 i 5.
A method of detecting a-synuclein oligomers in vitro, comprising adding the antibody according to any one of embodiments 27-42 to a biological sample comprising or suspected of comprising soluble a-synuclein; and detecting and measuring a concentration of any complex formed between the antibody and soluble a-synuclein. 
Postupak za detektiranje topivog a-sinukleina in vitro, koji sadrži dodavanje antitijela prema bilo kojem od zahtjeva 12-14 u biološki uzorak koji sadrži ili se sumnja da sadrži topivi a-sinuklein; i detektiranje i mjerenje koncentracije bilo kojeg kompleksa formiranog između antitijela i topivog a-sinukleina.
The antibody of claim 1, wherein the antibody inhibits Mac-1 binding to the fibrin or fibrinogen YC domain. 
Protutijelo iz patentnog zahtjeva 1, pri čemu protutijelo inhibira vezanje Mac-1 za YC domenu fibrina ili fibrinogena.
Other proliferative disorders can also be treated according to the disclosure, including for example hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od proliferativnog poremećaja izabranog između hiperplazija, fibroze, angiogeneze, psorijaze, ateroskleroze, stenoze ili restenoze nakon angioplastike, i drugih bolesti naznačenih proliferacijom glatkih mišića u krvnim žilama.
The fusion polypeptide according to claim 9, wherein the C5 binding polypeptide is in dimeric form. The fusion polypeptide according to claim 1, comprising a half-life extending moiety which increases the half-life of the C5 binding polypeptide in vivo. 
Polipeptid koji veže C5 sukladno zahtjevu 11, koji dalje sadrži skupinu koja produžava poluživot, a koja povećava poluživot polipeptida koji veže C5 in vivo, pri čemu je spomenuta skupina koja produžava poluživot Fc domena protutijela.
The term (C1-6) acyl and (C1-15) acyl represent an acyl group derived from a carboxylic acid having respectively 1-6 and 1-15 carbon atoms. 
Termin (C1.4) acil i (C,.,5) acil predstavljaju acilnu skupinu koju se izvodi iz karboksilnih kiselina s 1-6 odnosno 1-15 atoma ugljika.
80 mg of this material was used as the substrate, and 80 mg of a 1:1 mixture of glycerin and propylene glycol was loaded on this substrate. 
80 mg ovog materijala koristi se kao supstrat, a 80 mg 1:1 smjese glicerina i propilen-glikola napuni se na ovaj supstrat.
The aqueous pharmaceutical suspension according to claim 3, wherein the sweetener system comprises, by weight/volume (g/100 mL), 20% of sucrose and 10% of xylitol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav sladila sadrži, težinski/volumno (g/100 ml), otprilike 20 % saharoze i otprilike 10 % ksilitola.
Xaa2 is Trp or an analog of Trp, wherein the analog of Trp has increased hydrophobic character as compared with Trp and is an analog having: an alkoxy substituent having 1 to 5 carbon atoms at the 5 position of tryptophan, optionally 5-methoxytryptophan; or 
Xaa2 je Trp ili njegov analog, gdje analog od Trp ima niži alkanoilni supstituent na položaju 1 triptofana ima pojačan hidrofobni karakter u odnosu na Trp, uz uvjet da ako Xaa3 je Trp, Xaa2 je analog od Trp;
A kit comprising a container containing a pharmaceutical composition containing the peptide according to any one of claims 1 to 4 or the activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form. 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanicu u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku;
R2n is independently selected from optionally substituted C1-C8 alkyl, optionally substituted C6-C12 aryl, OR2b, and NR2cR2d, wherein said optional substituents are one to three R10 groups; R2b is detected from 11 and optionally substituted C1-C8 alkyl, wherein said optional substituents are one to three R10 groups; 
R* je nezavisno odabran od proizvoljno supstituiranog C;-Cg alkila, proizvoljno supstituiranog Cg-C;, arila, OR", te NRČR, pri čemu su navedeni nezavisni supstituenti jedna do tri R"* skupine; R? je odabran od H i proizvoljno supstituiran C,-Cz alkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R'" skupine;
The use of the (S)-enantiomer of embodiment (1) in the preparation of a medicament for the treatment of a disease or condition ameliorated or alleviated by the inhibition of a voltage-gated sodium channel in mammal. 
Upotreba (S)-enantiomera u skladu s patentnim zahtjevom 1 u pripravi medikamenta za liječenje bolesti ili stanja koja se ublažuju ili olakšavaju inhibiranjem naponskog natrijskog kanala kod sisavca.
One embodiment is a process for producing a pharmaceutical composition which comprises providing a solid powder of a therapeutically effective amount of at least one therapeutic agent and a solid powder comprising a medium chain fatty acid salt, and suspending the solid powders in a hydrophobic medium, to produce a suspension containing in solid form the therapeutic agent and the medium chain fatty acid salt, thereby producing the pharmaceutical composition, wherein the pharmaceutical composition contains 10% or more by weight of medium chain fatty acid salt. 
Postupak za proizvodnju farmaceutskog pripravka kao što je navedeno u bilo kojem od patentnih zahtjeva 1-15 naznačen time da sadrži osiguravanje krutog oblika terapeutski učinkovite količine oktreotida i kruti oblik koji sadrži sol masne kiseline srednjeg lanca, te suspendiranje krutih oblika u hidrofobnom mediju, da se dobije suspenzija koja sadrži oktreotid u krutom obliku i sol masne kiseline srednjeg lanca, čime se proizvodi farmaceutski pripravak, pri čemu farmaceutski pripravak sadrži 10 masenih % ili više soli masne kiseline srednjeg lanca.
an antibody comprising a light chain sequence comprising the amino acid sequence SEQ ID No. 
antitijelo koje sadrži sekvenciju lakog lanca koji sadrži aminokiselinsku sekvenciju SEQ ID No.
Discharge device according to claim 1, wherein the valve element is depressible against the biasing force of the spring from the intermediate position into the second position. 
Naprava za pražnjenje prema bilo kojem prethodnom zahtjevu, naznačena time, da se element ventila (5) može pritisnuti dolje protiv sile prenaprezanja iz međupoložaja u drugi položaj, ponajprije pomoću elementa za pokretanje (17), kao što je glava za pražnjenje.
An orally dispersing tablet comprising less than or equal to 20 mg of budesonide or a solvate or ester thereof, and at least one pharmaceutically acceptable ingredient which facilitates the dispersal of the tablet in the oral cavity, wherein the tablet is suitable for topical administration of budesonide in the upper gastrointestinal tract. 
PATENTNI ZAHTJEVI Tableta za oralno disperziranje koja sadrži manje ili jednako 20 mg budezonida ili njegovog solvata ili estera i najmanje jedan farmaceutski prihvatljiv sastojak koji omogućuje razgradnju tablete u usnoj šupljini, naznačeno time da je tableta pogodna za topikalnu primjenu budezonida u gornjem gastrointestinatnom traktu.
A host cell comprising the nucleic acid or the expression vector according to claim 5. The host cell according to claim 7, wherein said host cell is an antigen presenting cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
The holes 217 and the corresponding openings 218 in the second layer 212 form the preferential passages for the outflow of the vapor-phase perspiration from the first layer 211 outwardly. 
Tkanina u skladu s patentnim zahtjevima 10 i 11, naznačena time, da rupe (217, 317) i odgovarajući otvori (218, 318) u drugom sloju (212) tvore navedene preferencijalne prolaze za paru iz navedenog prvog sloja (211) prema van.
A method of making the antibody of any one of claims 1 to 6, in a polyploid yeast culture that stably expresses and secretes into the culture medium at least 10-25 mg/liter of said antibody, comprising: 
Postupak proizvodnje protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 5 u kulturi poliploidnog kvasca koji stabilno eksprimira i izlučuje u medij za kulturu najmanje 10-25 mg/l navedenog protutijela, naznačen time što se sastoji u:
provided that when n is 0, X is selected from CH2, CHR5, and C(R5)2; and R2 are each independently selected from alkoxy, alkyl, and halo; when s is 1, 2, 3, or 4, each R5 on the ring is independently selected from alkoxy, alkyl, and aryl, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
R! i R* su svaki nezavisno izabrani između alkoksi, alkil, i halogen; i kada s je 2, 3,1li 4, svaki R* na prstenu je nezavisno izabran između alkoksi, alkil, 1 aril, gdje alkil po izboru može formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine; uz uvjet da su dva heterociklička prstena koja supstituiraju imidazolske prstene identični; postupak obuhvaća:
Said sub-doses may be formulated as unit dosage forms, for example, containing 0.05 mg to 250 mg or 750 mg, and in particular 0.5 to 50 mg of active ingredient per unit dosage form. 
Spomenute subdoze mogu se oblikovati kao jedinični oblici za doziranje, na primjer oni koji sadržavaju 0,05 mg do 250 mg ili 750 mg, te posebice od 0,5 do 50 mg djelatne tvari po jediničnom obliku za doziranje.
The aqueous agrochemical suspension according to claim 1 or 6, wherein the suspension is a formulation and the amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 5 to 60 parts by weight, the amount of the inorganic thickener is within a range of 4 to 30 parts by weight and the amount of the dispersant is within a range of 5 to 85 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1 ili 6, gdje suspenzija je formulacija i količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 5 do 60 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 4 do 30 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 5 do 85 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.